The Competition Commission of India has approved Mankind Pharma’s proposed acquisition of Bharat Serum and Vaccines for Rs 13,630 crore. Mankind Pharma is a publicly traded company engaged in the development, manufacturing and marketing of a wide range of pharmaceutical formulations.
With this acquisition, Mankind Pharma will acquire 100% stake in BSV. The Company specializes in the research, development, manufacturing and sales of pharmaceutical formulations, active pharmaceutical ingredients and dietary supplements. BSV is also recognized as a leader in women’s health care, assisted reproductive technology, and emergency medicine.
This strategic move strengthens Mankind Pharma’s position in the Indian women’s health and infertility drugs market, providing access to high-barrier products in the critical care space backed by established R&D capabilities. is expected to be provided.
The transaction exceeded the threshold for large-scale mergers and acquisitions and required CCI approval to ensure compliance with regulations promoting fair competition and preventing unfair business practices.
